Trial Outcomes & Findings for Clinical Biocompatibility Evaluation of Contact Lens Coatings (NCT NCT03034928)

NCT ID: NCT03034928

Last Updated: 2020-02-18

Results Overview

Percent of solution-related corneal staining area was assessed first in each of the 5 corneal regions: central, superior, nasal, inferior, and temporal. The average of corneal staining area was then calculated as the average over all 5 regions. A higher percentage reflects more damage to the corneal surface. Both eyes contributed to the analysis. No hypotheses were formulated; no inferences were made and only descriptive statistics were used in the reporting.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

33 participants

Primary outcome timeframe

Day 1 after 2 hours of wear, each product

Results posted on

2020-02-18

Participant Flow

Subjects were recruited from 1 study center located in the United States (US).

All 33 subjects enrolled were randomized. This reporting group includes all randomized subjects (33).

Participant milestones

Participant milestones
Measure
Test 1/Control 1, Then Control 2/Test 2
Contact lens with investigational coating 1 in right eye, with balafilcon A contact lens in left eye during Period 1, followed by balafilcon A contact lens in right eye, with contact lens with investigational coating 2 in left eye during Period 2. Each lens pair worn contralaterally for approximately 2 hours, with 2 to 8 days between pairs.
Test 2/Control 2, Then Control 1/Test 1
Contact lens with investigational coating 2 in right eye, with balafilcon A contact lens in left eye during Period 1, followed by balafilcon A contact lens in right eye, with contact lens with investigational coating 1 in left eye during Period 2. Each lens pair worn contralaterally for approximately 2 hours, with 2 to 8 days between pairs.
Control 1/Test 1, Then Test 2/Control 2
Balafilcon A contact lens in right eye, with contact lens with investigational coating 1 in left eye during Period 1, followed by contact lens with investigational coating 2 in right eye, with balafilcon A contact lens in left eye during Period 2. Each lens pair worn contralaterally for approximately 2 hours, with 2 to 8 days between pairs.
Control 2/Test 2, Then Test 1/Control 1
Balafilcon A contact lens in right eye, with contact lens with investigational coating 2 in left eye during Period 1, followed by contact lens with investigational coating 1 in right eye, with balafilcon A contact lens in left eye during Period 2. Each lens pair worn contralaterally for approximately 2 hours, with 2 to 8 days between pairs.
Period 1, First 2 Hours of Wear
STARTED
8
8
9
8
Period 1, First 2 Hours of Wear
COMPLETED
8
8
9
8
Period 1, First 2 Hours of Wear
NOT COMPLETED
0
0
0
0
Washout Period Between Lens Wear
STARTED
8
8
9
8
Washout Period Between Lens Wear
COMPLETED
8
8
9
8
Washout Period Between Lens Wear
NOT COMPLETED
0
0
0
0
Period 2, Second 2 Hours of Wear
STARTED
8
8
9
8
Period 2, Second 2 Hours of Wear
COMPLETED
8
8
9
8
Period 2, Second 2 Hours of Wear
NOT COMPLETED
0
0
0
0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Clinical Biocompatibility Evaluation of Contact Lens Coatings

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Overall
n=33 Participants
Contact lens with investigational coatings and balafilcon A contact lens worn contralaterally during Period 1 and Period 2.
Age, Continuous
46.9 years
STANDARD_DEVIATION 14.46 • n=5 Participants
Sex: Female, Male
Female
26 Participants
n=5 Participants
Sex: Female, Male
Male
7 Participants
n=5 Participants
Race/Ethnicity, Customized
White
27 Participants
n=5 Participants
Race/Ethnicity, Customized
Black or African American
5 Participants
n=5 Participants
Race/Ethnicity, Customized
American Indian or Alaska Native
0 Participants
n=5 Participants
Race/Ethnicity, Customized
Asian
1 Participants
n=5 Participants
Race/Ethnicity, Customized
Native Hawaiian or Other Pacific Islander
0 Participants
n=5 Participants
Race/Ethnicity, Customized
Multi-Racial
0 Participants
n=5 Participants
Race/Ethnicity, Customized
Other
0 Participants
n=5 Participants

PRIMARY outcome

Timeframe: Day 1 after 2 hours of wear, each product

Population: This analysis population includes all randomized subjects who satisfied protocol-specified criteria (Full Analysis Set).

Percent of solution-related corneal staining area was assessed first in each of the 5 corneal regions: central, superior, nasal, inferior, and temporal. The average of corneal staining area was then calculated as the average over all 5 regions. A higher percentage reflects more damage to the corneal surface. Both eyes contributed to the analysis. No hypotheses were formulated; no inferences were made and only descriptive statistics were used in the reporting.

Outcome measures

Outcome measures
Measure
Test 1
n=33 Participants
Contact lens with investigational coating 1 worn for approximately 2 hours during Period 1 or Period 2
Control 1
n=33 Participants
Balafilcon A contact lens worn contralaterally to Test 1 for approximately 2 hours during Period 1 or Period 2
Test 2
n=33 Participants
Contact lens with investigational coating 2 worn for approximately 2 hours during Period 1 or Period 2
Control 2
n=33 Participants
Balafilcon A contact lens worn contralaterally to Test 2 for approximately 2 hours during Period 1 or Period 2
Average Percent Area of Solution-related Corneal Staining
7.01 percentage of area
Standard Deviation 10.54
12.82 percentage of area
Standard Deviation 17.93
13.54 percentage of area
Standard Deviation 17.20
7.58 percentage of area
Standard Deviation 10.34

Adverse Events

Test 1

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Test 2

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Control

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Sr CDMA Project Lead, GCRA - Vision Care

Alcon, A Novartis Division

Phone: 1-888-451-3937

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place